{"organizations": [], "uuid": "a5258caeba0a333b9e554ba0366bdba03c392b7c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-contravirs-txl-granted-orphan-drug/brief-contravirs-txl-granted-orphan-drug-designation-for-treatment-of-hbv-in-pediatric-population-idUSFWN1QC0V2", "country": "US", "domain_rank": 408, "title": "BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T15:30:00.000+02:00", "replies_count": 0, "uuid": "a5258caeba0a333b9e554ba0366bdba03c392b7c"}, "author": "", "url": "https://www.reuters.com/article/brief-contravirs-txl-granted-orphan-drug/brief-contravirs-txl-granted-orphan-drug-designation-for-treatment-of-hbv-in-pediatric-population-idUSFWN1QC0V2", "ord_in_thread": 0, "title": "BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "hbv", "sentiment": "negative"}, {"name": "contravir pharmaceuticals inc", "sentiment": "none"}, {"name": "hbv in pediatric population reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 22, 2018 / 1:31 PM / in 9 minutes BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population Reuters Staff 1 Min Read Feb 22 (Reuters) - Contravir Pharmaceuticals Inc: * CONTRAVIR PHARMACEUTICALS ANNOUNCES TXLâ„¢ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-22T15:30:00.000+02:00", "crawled": "2018-02-22T15:48:59.034+02:00", "highlightTitle": ""}